<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Finasteride: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Finasteride: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Finasteride: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12473" href="/d/html/12473.html" rel="external">see "Finasteride: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F171302"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Propecia;</li>
<li>Proscar</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866897"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Finasteride;</li>
<li>AG-Finasteride;</li>
<li>APO-Finasteride;</li>
<li>Auro-Finasteride;</li>
<li>BIO-Finasteride;</li>
<li>DOM-Finasteride;</li>
<li>JAMP-Finasteride;</li>
<li>M-Finasteride;</li>
<li>MINT-Finasteride;</li>
<li>PMS-Finasteride;</li>
<li>Propecia;</li>
<li>Proscar;</li>
<li>RAN-Finasteride [DSC];</li>
<li>RIVA-Finasteride;</li>
<li>SANDOZ Finasteride;</li>
<li>SANDOZ Finasteride A;</li>
<li>TEVA-Finasteride</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F171346"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        5 Alpha-Reductase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F171305"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="715cdd3a-1445-4dcc-82fe-013e6441d236">Androgenetic alopecia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Androgenetic alopecia (male pattern hair loss):</b> Males: Oral: 1 mg once daily. Continue for at least 12 months to assess full effect; continued daily use is required to sustain benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Donovan.2019','lexi-content-ref-10365924','lexi-content-ref-10674382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Donovan.2019','lexi-content-ref-10365924','lexi-content-ref-10674382'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64ef9771-0186-450c-8cac-9fbc347a4341">Benign prostatic hyperplasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Benign prostatic hyperplasia (alternative agent): Note: </b>Reserve use for patients with significantly enlarged prostates (prostate volume &gt;30 mL, prostate-specific antigen &gt;1.5 ng/mL, or palpable prostate enlargement on digital rectal exam) or those with hematuria associated with benign prostatic hyperplasia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34384237','lexi-content-ref-34384236','lexi-content-ref-McVary.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34384237','lexi-content-ref-34384236','lexi-content-ref-McVary.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 5 mg once daily (either as a single agent or in combination with an alpha-1 adrenergic antagonist); 6 to 12 months of treatment is usually needed to improve symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34384237','lexi-content-ref-14681504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34384237','lexi-content-ref-14681504'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="96a7e244-6070-4f1a-a224-02e4ca447b3b">Hirsutism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hirsutism (alternative agent) (off-label use):</b>
<b>Note:</b> Typically given in addition to oral contraceptives (OCs) if inadequate response to OCs is observed after 6 months. May be considered as initial therapy for females who cannot conceive or who are using reliable contraception.</p>
<p style="text-indent:-2em;margin-left:4em;">Females: Oral: 2.5 to 5 mg once daily. Assess response at 6-month intervals before adjusting dose, adding additional agents, or switching to alternative therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barbieri.2019','lexi-content-ref-29522147']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barbieri.2019','lexi-content-ref-29522147'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991234"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8846625','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8846625','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (highly protein bound, moderate V<sub>d</sub>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound, moderate V<sub>d</sub>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988472"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution (finasteride is metabolized extensively in the liver)</p></div>
<div class="block doe drugH1Div" id="F171306"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F54950989"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Sexual dysfunction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Finasteride may cause sexual dysfunction, including <b>impotence</b>, <b>decreased libido</b>, <b>ejaculatory disorder</b>, and <b>sexual disorder</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29447628','lexi-content-ref-26678956','lexi-content-ref-27475241','lexi-content-ref-32317131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29447628','lexi-content-ref-26678956','lexi-content-ref-27475241','lexi-content-ref-32317131'])">Ref</a></span>), which may persist after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31399423','lexi-content-ref-30651009','lexi-content-ref-33175100','lexi-content-ref-32317131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31399423','lexi-content-ref-30651009','lexi-content-ref-33175100','lexi-content-ref-32317131'])">Ref</a></span>). Of note, it has been hypothesized that persistent sexual dysfunction may contribute to psychological adverse reactions (eg, <b>anxiety </b>and <b>depression</b>) and <b>suicidal ideation</b> and <b>suicidal tendencies</b> in younger patients treated for alopecia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33175100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33175100'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose and time-related; may be related to antiandrogenic effects and subsequent decreased nitric oxide in the corpus cavernosum (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27475241','lexi-content-ref-30209896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27475241','lexi-content-ref-30209896'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; may begin after ~6 months of therapy and peak during the first year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29447628','lexi-content-ref-26678956','lexi-content-ref-27475241','lexi-content-ref-12639651']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29447628','lexi-content-ref-26678956','lexi-content-ref-27475241','lexi-content-ref-12639651'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Independent risk factors include older patients and benign prostatic hyperplasia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27475241','lexi-content-ref-17596576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27475241','lexi-content-ref-17596576'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher dosage of finasteride (5 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27475241']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27475241'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Length of therapy ≥1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27475241']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27475241'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F171269"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Genitourinary: Impotence (5% to 19%)<span class="lexi-table-link-container"> (<a aria-label="Impotence table link" class="lexi-table-link" data-table-id="lexi-content-impotence" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-impotence')">table 1</a>)</span><span class="table-link" style="display:none;">Impotence</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Impotence" frame="border" id="lexi-content-impotence" rules="all">
<caption style="text-align:center;">
<b>Finasteride: Adverse Reaction: Impotence</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Finasteride)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Finasteride)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg per day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">BPH</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">768</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">737</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">BPH</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1524</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1516</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Year 1</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">BPH</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1524</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1516</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Years 2 to 4</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (1%), orthostatic hypotension (9%)<span class="lexi-table-link-container"> (<a aria-label="Orthostatic Hypotension table link" class="lexi-table-link" data-table-id="lexi-content-orthostatic-hypotension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-orthostatic-hypotension')">table 2</a>)</span><span class="table-link" style="display:none;">Orthostatic Hypotension</span>, peripheral edema (1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Orthostatic Hypotension" frame="border" id="lexi-content-orthostatic-hypotension" rules="all">
<caption style="text-align:center;">
<b>Finasteride: Adverse Reaction: Orthostatic Hypotension</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Finasteride)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Finasteride)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">BPH</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">768</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">737</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (2% to 10%)<span class="lexi-table-link-container"> (<a aria-label="Decreased Libido table link" class="lexi-table-link" data-table-id="lexi-content-decreased-libido" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreased-libido')">table 3</a>)</span><span class="table-link" style="display:none;">Decreased Libido</span>, gynecomastia (1% to 2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Decreased Libido" frame="border" id="lexi-content-decreased-libido" rules="all">
<caption style="text-align:center;">
<b>Finasteride: Adverse Reaction: Decreased Libido</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Finasteride)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Finasteride)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">BPH</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">768</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">737</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">BPH</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1524</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1516</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Year 1</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">BPH</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1524</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1516</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Years 2 to 4</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Male pattern hair loss</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">945</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">934</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast tenderness (≤1%), decreased ejaculate volume (2% to 4%), ejaculatory disorder (≤7%)<span class="lexi-table-link-container"> (<a aria-label="Ejaculatory Disorder table link" class="lexi-table-link" data-table-id="lexi-content-ejaculatory-disorder" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ejaculatory-disorder')">table 4</a>)</span><span class="table-link" style="display:none;">Ejaculatory Disorder</span>, prostate cancer - high grade (2%) (Thompson 2003, Thompson 2013), sexual disorder (3%)<span class="lexi-table-link-container"> (<a aria-label="Sexual Disorder table link" class="lexi-table-link" data-table-id="lexi-content-sexual-disorder" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-sexual-disorder')">table 5</a>)</span><span class="table-link" style="display:none;">Sexual Disorder</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Ejaculatory Disorder" frame="border" id="lexi-content-ejaculatory-disorder" rules="all">
<caption style="text-align:center;">
<b>Finasteride: Adverse Reaction: Ejaculatory Disorder</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Finasteride)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Finasteride)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">BPH</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">768</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">737</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">BPH</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1524</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1516</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Year 1</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">BPH</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1524</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1516</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Years 2 to 4</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Male pattern hair loss</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">945</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">934</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Sexual Disorder" frame="border" id="lexi-content-sexual-disorder" rules="all">
<caption style="text-align:center;">
<b>Finasteride: Adverse Reaction: Sexual Disorder</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Finasteride)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Finasteride)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">BPH</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">768</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">737</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinitis (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Genitourinary: Malignant neoplasm of the breast (men)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (T-cell mediated localized exanthematous pustulosis) (Tresch 2011), erythematous rash (erythema annulare centrifugum) (Al Hammadi 2007), fixed drug eruption (Oyama 2009), skin photosensitivity (Yamade 2021), urticaria (Moreno-Fernandez 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hemospermia (Fouda 2017), male infertility (temporary) (Chiba 2010; Ricci 2012), testicular pain (Pereira 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity angiitis (Lear 1996)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (Nguyen 2021), depression (may persist after discontinuation) (Nguyen 2021, Welk 2017), suicidal ideation (may persist after discontinuation) (Ali 2015; Nguyen 2021, Welk 2017), suicidal tendencies (may persist after discontinuation) (Nguyen 2021, Welk 2017)</p></div>
<div class="block coi drugH1Div" id="F171283"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to finasteride or any component of the formulation; pregnancy or patients who may potentially be pregnant.</p></div>
<div class="block war drugH1Div" id="F171266"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diminished urinary flow: Carefully monitor patients with a large residual urinary volume or severely diminished urinary flow for obstructive uropathy; these patients may not be candidates for finasteride therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; finasteride is extensively metabolized in the liver.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostate cancer: When compared to placebo, 5-alpha-reductase inhibitors (5-ARIs) have been associated with an increase in the incidence of high-grade prostate cancers; 5-ARIs are not approved in the United States or Canada for the prevention of prostate cancer.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Females: Active ingredient of crushed or broken tablets can be absorbed through the skin; unbroken tablets are coated, which prevents contact with the active ingredient during normal handling. Patients who could become pregnant should not touch or handle crushed or broken tablets.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Other urological diseases (including prostate cancer) should be ruled out before initiating (in benign prostatic hyperplasia [BPH] management). Not indicated for use in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Duration of therapy: For BPH, a minimum of 6 months of treatment may be necessary to determine whether an individual will respond to finasteride; for male pattern hair loss, daily use for ≥3 months may be required before benefit is observed (withdrawal of treatment leads to reversal of hair growth effect within 12 months).</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostate specific antigen monitoring: Reduces prostate specific antigen (PSA) concentration by ~50% within 6 months of treatment. Reestablish new PSA baseline after initiation. A confirmed PSA increase while on this medication, even if within normal limits, may be associated with an increased risk for prostate cancer and should be evaluated. Finasteride does not interfere with free PSA levels.</p></div>
<div class="block foc drugH1Div" id="F171276"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Propecia: 1 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Proscar: 5 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 5 mg</p></div>
<div class="block geq drugH1Div" id="F171262"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F171285"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Finasteride Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $2.71 - $2.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.11 - $3.19</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Propecia Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $4.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Proscar Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $6.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866898"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Propecia: 1 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Proscar: 5 mg [contains corn starch, fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 5 mg</p></div>
<div class="block adm drugH1Div" id="F171280"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> May be administered with or without meals. Pregnant patients and patients who could become pregnant should not touch or handle crushed or broken tablets.</p></div>
<div class="block hazard drugH1Div" id="F49104520"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F171279"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Androgenetic alopecia (male pattern hair loss):</b> Treatment of male pattern hair loss in men.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Efficacy in bitemporal recession has not been established.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Benign prostatic hyperplasia:</b> Treatment (monotherapy) of symptomatic benign prostatic hyperplasia (BPH) to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of need for BPH-related surgery; used in combination with an alpha-1 adrenergic antagonist to reduce the risk of symptomatic progression.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Not approved for the prevention of prostate cancer.</p></div>
<div class="block off-label drugH1Div" id="F25725588"><span class="drugH1">Use: Off-Label: Adult</span><p>Hirsutism</p></div>
<div class="block mst drugH1Div" id="F171352"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Finasteride may be confused with dutasteride, furosemide</p>
<p style="text-indent:-2em;margin-left:4em;">Proscar may be confused with Prograf, ProSom, Provera, PROzac</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F171339"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F171270"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F53559903"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Although use is contraindicated in patients who may potentially be pregnant, finasteride has been evaluated for various indications in premenopausal patients, including the treatment of hirsutism and female pattern hair loss. Adequate contraception is recommended (ACOG 2018; Carmina 2019; ES [Martin 2018]; Hu 2019; Iamsumang 2020). Contraception should be used during treatment and for at least 30 days after the last finasteride dose (Carmina 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Patients who could become pregnant should not touch or handle crushed or broken tablets.</p>
<p style="text-indent:0em;margin-top:2em;">Finasteride is present in semen. Male infertility and poor seminal quality have been reported and may be reversible upon discontinuation of finasteride. Adverse events may be dose related and, less likely, associated with doses used for male pattern hair loss (Zakhem 2019).</p></div>
<div class="block pri drugH1Div" id="F171286"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to finasteride may lead to abnormal development of the male genital tract. Pregnancy outcome information following inadvertent finasteride exposure during pregnancy is limited (AlSaad 2018). Use is contraindicated during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Pregnant patients are advised to avoid contact with crushed or broken tablets and immediately wash the contact area with soap and water if exposure occurs.</p></div>
<div class="block brc drugH1Div" id="F171287"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if finasteride is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients who could become pregnant should not touch or handle crushed or broken tablets.</p></div>
<div class="block mop drugH1Div" id="F171274"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">To interpret serial prostate-specific antigens (PSAs), establish a new PSA baseline ≥6 months after treatment initiation and monitor PSA periodically thereafter; International Prostate Symptom Score (baseline and 3 to 12 months after treatment initiation); urinalysis (baseline); objective and subjective signs of relief of benign prostatic hyperplasia and lower urinary tract symptoms (AUA [Lerner 2021a; McVary 2022; manufacturer's labeling).</p></div>
<div class="block pha drugH1Div" id="F171265"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Finasteride competitively inhibits type II 5-alpha reductase, resulting in inhibition of the conversion of testosterone to dihydrotestosterone and markedly suppresses serum dihydrotestosterone levels</p></div>
<div class="block phk drugH1Div" id="F171282"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Dihydrotestosterone levels return to normal within 14 days of discontinuation of treatment; BPH: Prostate volume returns to baseline within ~3 months after discontinuation; Male pattern baldness: Reversal of increased hair count within 12 months</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>dss</sub>: 76 L </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~90% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic (extensive) via CYP3A4; two active metabolites (&lt;20% activity of finasteride) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Mean: 5 mg: ~63%; 1 mg: 65% (not affected by food)  </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination, serum: 5 to 6 hours (range: 3 to 16 hours); Elderly (≥70 years):  8 hours (range: 6 to 15 hours)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 1 to 2 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (57%) and urine (39%; as metabolites)</p></div>
<div class="block phksp drugH1Div" id="F51192567"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Urinary excretion of metabolites was decreased in patients with renal impairment. This decrease was associated with an increase in fecal excretion of metabolites. Plasma concentrations of metabolites were significantly higher in patients with renal impairment (based on a 60% increase in total radioactivity AUC).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Mean AUC<sub>0-24</sub> increases 15%.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F171288"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Finiscar | Finorma | Phinax | Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Anatine | Andropel | Capilfor | Daric | Finasteride prost northia | Finasterin | Finax | Finprostat | Ivix Fin | Nasteril | Pelicrep | Propecia | Proscar | Prosmin | Prostanil | Prostanovag | Prostene | Prunus | Q prost alopex | Sutrico | Tresaride | Tricofarma | Urototal | Vetiprost</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Androfin | Finasterid +Pharma | Finasterid Actavis | Finasterid Alternova | Finasterid G.L. | Finasterid Interpharm | Finasterid Pfizer | Finasterid Ranbaxy | Finasterid ratiopharm | Finasterid sandoz | Finasterid Stada | Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apl Finasteride | Apo finasteride | Auro finasteride | Finapen | Finasta | Finasteride alphapharm | Finasteride an | Finasteride ga | Finasteride gh | Finasteride rbx | Finide | Finnacar | Pharmacor finasteride | Pharmacy choice finasteride | Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Alopec | Pronor | Prosfin | Recur</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Finasteride EG | Finasteride Mylan | Finasteride ranbaxy | Finasteride sandoz | Finasteride teva | Proscar</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Erestrid</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Finacon | Hyplafin | Penester | Proscar</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alfasin | Calvin | Capyla-hair | Excalv | Fenasten | Fendical | Finalop | Finapecia | Finarid | Finastec | Finasterida | Finastil | Nasterid | Nasterid a | Pracap | Pro hair | Pronasteron | Propecia | Proscar | Prostide | Reduscar</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Alocapil | Andropecia biorga | Finacapil | Finasterax | Finasterid Actavis | Finasterid Helvepharm | Finasterid Mepha | Finasterid Orion | Finasterid sandoz | Finasterid Spirig | Finasterid spirig hc | Finasterid Streuli | Finasterid Teva | Finasterid zentiva | Proscar</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Erestrid</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Apeplus | Finalgen | Prohair | Proscar</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai shi lie | Bao li an | Jun da | Ka bo | Lan le | Propecia | Proscar | Pu lie an | Qi yue | Qian nuo lin | Shu bang | Tian shu xin | Xian li xiao | Xing bao | Ya bao li tong | Yi ru te | Yi shu sheng | Yi you rui xin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Apeplus | Binfin | Caosol | Finaspros | Finasteride MK | Finhet | Fistrin | Nasterol | Propecia</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Adafin | Androfin | Apo Finas | Finajelf | Finanorm | Finard | Finasterid Actavis | Finasterid aurovitas | Finasterid mylan | Finpros | Gefin | Hyplafin | Milten | Penester | Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Capila | Finahair | Finamed | Finapil | Finapuren | Finaristo | Finascar | Finasterid | Finasterid 1 A Pharma | Finasterid abz | Finasterid amarox | Finasterid Aristo | Finasterid ascend | Finasterid Aurobindo | Finasterid basics | Finasterid Beta | Finasterid Biomo | Finasterid bluefish | Finasterid ct | Finasterid dexcel | Finasterid Dura | Finasterid Esparma | Finasterid Heumann | Finasterid Hexal | Finasterid hormosan | Finasterid Medico | Finasterid nio | Finasterid puren | Finasterid ratiopharm | Finasterid sandoz | Finasterid Stada | Finasterid tecnimede | Finasterid Teva | Finasterid Uropharm | Finasterid Winthrop | Finural | Propecia | Proscar | Prosmin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Apeplus | Propecia | Proscar | Prostasax | Rowesteride</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Apeplus | Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Aindeem | Finasteride accord | Finasteride Portfarma | Finasteride teva | Penester | Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Finastura | Fincar | Prohair | Proscar | Prostat | Prostec</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Alocare | Arahormo | Capikern | Celganol | Finasterida Actavis | Finasterida Actavis Group | Finasterida Almus | Finasterida Alter | Finasterida Aphar | Finasterida Arafarma | Finasterida Aurobindo | Finasterida aurovitas | Finasterida Bexal | Finasterida biorga | Finasterida Cinfa | Finasterida Cinfamed | Finasterida Combix | Finasterida Davur | Finasterida Edigen | Finasterida ifc | Finasterida Kern Pharma | Finasterida Lareq | Finasterida Mabo | Finasterida normon | Finasterida Pensa | Finasterida Pharmacia | Finasterida Qualigen | Finasterida Ranbaxy | Finasterida Rimafar | Finasterida Sandoz | Finasterida Stada | Finasterida Tarbis | Finasterida Tecnigen | Finasterida Teva | Finasterida Vir | Finasterida Winthrop | Lambdaxel | Litace | Maxpil | Predser | Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Finasterid Alternova | Finasterid Copyfarm | Finasterid Ivax | Finasterid Orion | Finasterid Pfizer | Finasterid ratiopharm | Finasteride ranbaxy | Gefina | Propecia | Proscar | Prosterid | Tifisterid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Chibro proscar | Finasteride accord | Finasteride Actavis | Finasteride almus | Finasteride Alter | Finasteride arrow | Finasteride bailleul | Finasteride biogaran | Finasteride Cristers | Finasteride EG | Finasteride isomed | Finasteride Mylan | Finasteride Pfizer | Finasteride phr | Finasteride qualimed | Finasteride ranbaxy | Finasteride ratiopharm | Finasteride sandoz | Finasteride teva | Finasteride zydus | Finhair | Propecia</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Aindeem | Finasteride accord | Finasteride neolab | Finasteride Pfizer | Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Alsteride | Andropecia | Avielid | Finar | Finasteride/Sandoz | Finastir | Finazil | Finescar | Fisterid | Glopisine | Profin/U.S. Generics | Profinosa | Prohype | Propecia | Proscar | Prostafin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Finasterida Farmoz | Finasteride sandoz | Fincar | Fynasid | Maxteride | Pronor | Propecia | Proride | Proscar | Prosteride | Tensen</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Finasterid Farmal | Finasterid Genericon | Finasterid PharmaS | Fincar | Finpros | Mostrafin | Profin | Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Andofin | Finanorm | Finastep | Finasterid Teva | Finasteride Pharmacenter | Finestra | Finpros | Hyplafin | Proscar | Prosterid | Redupros | Sterakfin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Finaxal | Finired | Finpro | Proscar | Prosh | Prostacom | Prostide | Reprosid | Reprostom</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Finocar | Fintex | Fintrid | Profal | Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">ProAvenir | Procure | Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bio hair F | Curlzfin | F 1 | Finabald | Finacet | Finalo | Finap | Finara | Finaride | Finast | Finax | Fincar | Fincover | Finoric | Finpecia | Fintride | Fintross | Growpecia | Monast | Mpb | X pecia</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Carefinast | Finacapil | Finasteride AHCL | Finasteride Alter | Finasteride Aurobindo | Finasteride Biorga | Finasteride Doc | Finasteride EG | Finasteride FG | Finasteride fidia | Finasteride Germed | Finasteride Mylan | Finasteride pensa | Finasteride Pfizer | Finasteride pharmacare | Finasteride ranbaxy | Finasteride sandoz | Finasteride tecnimede | Finasteride zentiva | Finastid | Finerid | Finestar | Genaprost | Nafiprosil | Ormicton | Propecia | Proscar | Prostide | Ridestin | Sitas | Stecur | Terip</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Prohair | Propecia | Proscar | Prostacare</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Finasteride fci | Finasteride ski | Finasteride sn | Finasteride takeda teva | Propecia</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Binfin | Finagen | Finamax | Fincar | Finfive | Finide | Finone | Proscar | Prosfin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Allofina | Alocia | Alofia | Alofina | Alopec | Alopecid | Aloscan | Alpha m | Alphascar | Austeride | Baltman | Barofina | Bearfina | Bearimo | Bearremo | Bermona | Boryung finasterid | Bp care | Cj finasteride | CM pro | Cmfina | Daewoongbio finasteride | Damopecia | Damopesia | Danapecia | Dupina | Enpina | Enpiscar | Epinasi | Fanarid | Feelast | Filast | Fina | Fina s | Finaberin | Finacetin | Finad | Finadid | Finadron | Finagen | Finajin | Finamoa | Finapilo | Finapros | Finapul | Finari | Finaride | Finarin | Finarol | Finaron | Finarosin | Finas | Finascar | Finaset | Finaseta | Finasia | Finasidil | Finaskan | Finasro | Finastar | Finastea | Finastel | Finasten | Finastid | Finastin | Finasto | Finastone | Finatech | Finated | Finaten | Finateri | Finatra | Finawin | Finaz | Finazen | Fincar | Finice | Finote | Finsta | Finstar | Firoid | Fites | Freefina | Freestar | Frostart | Gromo | Hairfina | Hairgain | Hairpecia | Hairsmo | Hanall finasteride | Hanlim Finasteride | Hypina | Il yang finasterid | Inno.n finasteride | J fina | J pecia | Medipecia | Merina | Minefesia | Minopecia | Modeopesia | Mogrow | Momod | Momopecia | Mona | Monad | Monafeel | Monapecia | Monarid | Monasia | Monastar | Monastin | Mopecia | Moriturn | Mycia | Myfina | Newfesia | Newfina | Newrid | Nowscar | Panad | Panascar | Perocia | Pharmbio korea finasteride | Pinad | Pinagren | Pinastrion | Piroid | Procare | Proci | Profina | Prohwa | Pronad | Propecia | Propia | Prorid | Proscar | Prosmol | Prostar | Prosteride | Prostil | Qloid | Remonal | Samsung finasteride | Scarex | Scarteron | Scateride | Scateron | Skarex | Stenka | Terina | Tesfina | Tinase | Tropina | Unacia | Unapia | Uniteride | Uraid | Urofina | Urolead | Urorid | Uroscan | Wifina</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Finastekern | Finasteride bailleul | Propecia | Proscar | Prostacare | Steribo | Sterifine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Androfin | Antiprost | Finahair | Finast | Finasterid Actavis | Finasterid Teva | Finasteride accord | Finasteride Actavis | Finasteride Aurobindo | Finasteride Portfarma | Finasteride teva | Finster | Penester | Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Finasteride bailleul | Finasteride sandoz | Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Aindeem | Androfin | Finasterid Aurobindo | Finasterid Portfarma | Finasteride accord | Finasteride teva | Finster | Propecia | Proscar | Prostarinol | Ulgafen</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Chibro proscar | Finasteride gt</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Astari | Bioterifina | Borealis | Caosol | Capillaceous | Efadrit | Fhilterin | Fidamus | Filuxa | Finasterida | Finasterida landsteiner | Fiperben | Fixdater | Fostak | Hibiteron | Lostecin | Luxfil | Novaride | Olipp | Pilovait | Riterid Z | Steryx | Syndrex | Tycrops | Zentanor</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Finagen | Finaintas | Finapecia | Finast | Finastir | Fincar | Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Chibro proscar | Finasteride Focus | Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Finamed | Finasterid | Finasterid Aurobindo | Finasterid bmm pharma | Finasterid Pfizer | Propecia | Proscar | Prosterid</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Finpro | Fintral | Profal | Propecia | Proscar | Regen | Ricit</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Fasterid | Finast | Folcres | Fonasterin | Lopecia | Nasteril | Propecia | Proscar | Vetiprost</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Atepros | Figna 5 | Finaplasia | Finapros | Finarid | Finasia | Finast | Finflow | Finide | Finstal | Pelosta | Pronax | Propecia | Proscar | Prosta one | Prostab | Prostanus | Vexfin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Finarid m | Fincar | Finsocar | Genesis | Hairfin | Manfin | Proscar | Prosin | Prostryl | Prostryl TB | Sanrid | Trichogen</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Adaster | Androstatin | Androster | Antiprost | Apo Fina | Aprost | Finagen | Finahit | Finamef | Finanorm | Finapil | Finaran | Finasterid ratiopharm | Finasteride 1A Pharma | Finasteridum bluefish | Finiprost | Fintral | Finxta | Hyplafin | Lifin | Nezyr | Penester | Propecia | Proscar | Symasteride | Ulgafen | Uronezyr</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Propecia | Propecia propak | Proscar</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Finast | Finasterida | Finasterida Accord | Finasterida Almus | Finasterida Apceuticals | Finasterida Daquimed | Finasterida frosst | Finasterida generis | Finasterida mer | Finasterida mylan | Finasterida Vir | Finox | Hedox | Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Daric | Finastide</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Finiscar | Prohair | Propecia | Proscar | Prostacare</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Finanorm | Finasterid sandoz | Finasteride teva | Proscar</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Finasteride obl | Finasteride teva | Finpros | Penester | Proscar | Prosterid | Urofin | Zerlon</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo finasteride | Finasid | Finiscar | Pms finasteride | Prohair | Proscar</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Finasterid accord | Finasterid Actavis | Finasterid Alternova | Finasterid Arrow | Finasterid Aurobindo | Finasterid bmm pharma | Finasterid Orion | Finasterid sandoz | Finasterid Stada | Finasteride accord | Finasteride Medical Valley | Finasteride ranbaxy | Finasteride teva | Finpros | Propecia | Proscar | Prosterid</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Finas | Finast | Propecia | Proscar | Stercia</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Finpros | Hyplafin | Mostrafin | Propecia | Prostide</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Finajelf | Finamed | Finanorm | Finasterid Actavis | Finasterid Orion | Finasteride accord | Finpros | Penester | Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Benstat | Finas | Firide | Harifin | Propecia | Proscar | Proseride | Prosteride | Stercaar | Stercia 5 | Sterzar</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Chibro proscar</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Alofin | Dilaprost | Finarid | Finhair | Propecia | Proscar | Prosterit</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Binfin | Finaride | Finaspro | Finastate | Finta | Fynasee | Fynasid | Kinscar | Popie | Proleak | Propecia | Proscar | Prosteride | Prusc | Tensen</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Adenosterid | Binfin | Finast | Finasteride genepharm | Proscar | Prostan | Prosterid</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Finagen | Fintas</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Binafin | Finatas | Hpb | Ibear | Pluviton | Profugal | Propecia | Proscar | Tricox</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Finasterida | Nasterol | Propecia | Proscar | Prosdina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Accord Finasteride | Alopec | Fincar | Finide | Intas finasteride | Profina | Propecia | Proscar</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Fincar</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Binfin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.2017">
<a name="USP.2017"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17668547">
<a name="17668547"></a>Al Hammadi A, Asai Y, Patt ML, Sasseville D. Erythema annulare centrifugum secondary to treatment with finasteride. <i>J Drugs Dermatol</i>. 2007;6(4):460-463.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/17668547/pubmed" id="17668547" target="_blank">17668547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26133534">
<a name="26133534"></a>Ali AK, Heran BS, Etminan M. Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: A pharmacovigilance study. <i>Pharmacotherapy</i>. 2015;35(7):687-95. doi:10.1002/phar.1612<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/26133534/pubmed" id="26133534" target="_blank">26133534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29855987">
<a name="29855987"></a>AlSaad D, Lee BH, Al-Obaidly S. Finasteride use during pregnancy and early neonatal outcome: a case report. <i>Int J Clin Pharm</i>. 2018;40(4):803-805. doi:10.1007/s11096-018-0661-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/29855987/pubmed" id="29855987" target="_blank">29855987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29794677">
<a name="29794677"></a>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. <i>Obstet Gynecol</i>. 2018;131(6):e157-e171. doi: 10.1097/AOG.0000000000002656.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/29794677/pubmed" id="29794677" target="_blank">29794677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barbieri.2019">
<a name="Barbieri.2019"></a>Barbieri RL, Chang J. Management of hirsutism in premenopausal women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 29, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29522176">
<a name="29522176"></a>Barrionuevo P, Nabhan M, Altayar O, et al. Treatment options for hirsutism: a systematic review and network meta-analysis. <i>J Clin Endocrinol Metab</i>. 2018;103(4):1258-1264. doi: 10.1210/jc.2017-02052.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/29522176/pubmed" id="29522176" target="_blank">29522176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30785992">
<a name="30785992"></a>Carmina E, Azziz R, Bergfeld W, et al. Female pattern hair loss and androgen excess: a report from the Multidisciplinary Androgen Excess and PCOS Committee. <i>J Clin Endocrinol Metab</i>. 2019;104(7):2875-2891. doi:10.1210/jc.2018-02548<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/30785992/pubmed" id="30785992" target="_blank">30785992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21193189">
<a name="21193189"></a>Chiba K, Yamaguchi K, Li F, Ando M, Fujisawa M. Finasteride-associated male infertility. <i>Fertil Steril</i>. 2011;95(5):1786.e9-e11. doi:10.1016/j.fertnstert.2010.12.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/21193189/pubmed" id="21193189" target="_blank">21193189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Donovan.2019">
<a name="Donovan.2019"></a>Donovan J, Goldstein BG, Goldstein AO. Treatment of androgenetic alopecia in men. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 26, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29447628">
<a name="29447628"></a>Fertig RM, Gamret AC, Darwin E, Gaudi S. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review. <i>Dermatol Online J</i>. 2017;23(11):13030/qt24k8q743<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/29447628/pubmed" id="29447628" target="_blank">29447628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29090364">
<a name="29090364"></a>Fouda AM, Bazeed AM. Hematuria and hematospermia associated with the use of finasteride for the treatment of androgenic alopecia: a case report. <i>Drug Saf Case Rep</i>. 2017;4(1):14. doi:10.1007/s40800-017-0059-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/29090364/pubmed" id="29090364" target="_blank">29090364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31399423">
<a name="31399423"></a>Gray SL, Semla TP. Post-finasteride syndrome. <i>BMJ</i>. 2019;366:l5047. doi:10.1136/bmj.l5047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/31399423/pubmed" id="31399423" target="_blank">31399423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30604525">
<a name="30604525"></a>Hu AC, Chapman LW, Mesinkovska NA. The efficacy and use of finasteride in women: a systematic review. <i>Int J Dermatol</i>. 2019;58(7):759-776. doi:10.1111/ijd.14370<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/30604525/pubmed" id="30604525" target="_blank">30604525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32184564">
<a name="32184564"></a>Iamsumang W, Leerunyakul K, Suchonwanit P. Finasteride and its potential for the treatment of female pattern hair loss: evidence to date. <i>Drug Des Devel Ther</i>. 2020;14:951-959. doi:10.2147/DDDT.S240615<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/32184564/pubmed" id="32184564" target="_blank">32184564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26678956">
<a name="26678956"></a>Kaplan SA, Lee JY, Meehan AG, Kusek JW. Time course of incident adverse experiences associated with doxazosin, finasteride and combination therapy in men with benign prostatic hyperplasia: The MTOPS trial. <i>J Urol</i>. 2016;195(6):1825-1829. doi:10.1016/j.juro.2015.11.065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/26678956/pubmed" id="26678956" target="_blank">26678956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8871471">
<a name="8871471"></a>Lear JT, Byrne JP. Finasteride-related cutaneous vaculitis. <i>Postgrad Med J</i>. 1996;72(844):127. doi:10.1136/pgmj.72.844.127-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/8871471/pubmed" id="8871471" target="_blank">8871471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34384237">
<a name="34384237"></a>Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I, initial work-up and medical management. <i>J Urol.</i> 2021a;206(4):806-817. doi:10.1097/JU.0000000000002183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/34384237/pubmed" id="34384237" target="_blank">34384237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34384236">
<a name="34384236"></a>Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part II-surgical evaluation and treatment. <i>J Urol</i>. 2021b;206(4):818-826. doi:10.1097/JU.0000000000002184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/34384236/pubmed" id="34384236" target="_blank">34384236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10365924">
<a name="10365924"></a>Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. <i>J Am Acad Dermatol</i>. 1999;40(6, pt 1):930-937. doi:10.1016/s0190-9622(99)70081-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/10365924/pubmed" id="10365924" target="_blank">10365924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27475241">
<a name="27475241"></a>Liu L, Zhao S, Li F, et al. Effect of 5α-reductase inhibitors on sexual function: A meta-analysis and systematic review of randomized controlled trials. <i>J Sex Med</i>. 2016;13(9):1297-1310. doi:10.1016/j.jsxm.2016.07.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/27475241/pubmed" id="27475241" target="_blank">27475241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30651009">
<a name="30651009"></a>Maksym RB, Kajdy A, Rabijewski M. Post-finasteride syndrome - does it really exist? <i>Aging Male</i>. 2019;22(4):250-259. doi:10.1080/13685538.2018.1548589<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/30651009/pubmed" id="30651009" target="_blank">30651009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29522147">
<a name="29522147"></a>Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2018;103(4):1233-1257. doi:10.1210/jc.2018-00241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/29522147/pubmed" id="29522147" target="_blank">29522147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14681504">
<a name="14681504"></a>McConnell JD, Roehrborn CG, Bautista OM, et al; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. <i>N Engl J Med. </i>2003;349(25):2387-2398. doi:10.1056/NEJMoa030656.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/14681504/pubmed" id="14681504" target="_blank">14681504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-McVary.1">
<a name="McVary.1"></a>McVary KT. Medical treatment of benign prostatic hyperplasia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17596576">
<a name="17596576"></a>Moinpour CM, Darke AK, Donaldson GW, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. <i>J Natl Cancer Inst</i>. 2007;99(13):1025-1035. doi:10.1093/jnci/djm023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/17596576/pubmed" id="17596576" target="_blank">17596576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19814757">
<a name="19814757"></a>Moreno-Fernandez A, Mira Laguarda JM, Ruiz-Hornillos FJ, Rubio Sotes M. Urticarial rush due to finasteride. <i>Allergy</i>. 2010;65(3):405-406. doi:10.1111/j.1398-9995.2009.02165.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/19814757/pubmed" id="19814757" target="_blank">19814757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33175100">
<a name="33175100"></a>Nguyen DD, Marchese M, Cone EB, et al. Investigation of suicidality and psychological adverse events in patients treated with finasteride. <i>JAMA Dermatol</i>. 2021;157(1):35-42. doi:10.1001/jamadermatol.2020.3385<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/33175100/pubmed" id="33175100" target="_blank">33175100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19103375">
<a name="19103375"></a>Oyama N, Kaneko F. Solitary fixed drug eruption caused by finasteride. <i>J Am Acad Dermatol</i>. 2009;60(1):168-169. doi:10.1016/j.jaad.2008.07.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/19103375/pubmed" id="19103375" target="_blank">19103375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32317131">
<a name="32317131"></a>Pereira AFJR, Coelho TOA. Post-finasteride syndrome. <i>An Bras Dermatol</i>. 2020;95(3):271-277. doi:10.1016/j.abd.2020.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/32317131/pubmed" id="32317131" target="_blank">32317131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Propecia.2014.01">
<a name="Propecia.2014.01"></a>Propecia (finasteride) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; January 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Propecia.2014.01">
<a name="Propecia.2014.01"></a>Propecia (finasteride) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Proscar.2013.09">
<a name="Proscar.2013.09"></a>Proscar (finasteride) [prescribing information]. Jersey City, NJ: Organon LLC; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23377525">
<a name="23377525"></a>Ricci G, Martinelli M, Luppi S, et al. Finasteride and fertility: case report and review of the literature. <i>J Drugs Dermatol</i>. 2012;11(12):1511-1513.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/23377525/pubmed" id="23377525" target="_blank">23377525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30209896">
<a name="30209896"></a>Shin YS, Karna KK, Choi BR, Park JK. Finasteride and erectile dysfunction in patients with benign prostatic hyperplasia or male androgenetic alopecia. <i>World J Mens Health</i>. 2019;37(2):157-165. doi:10.5534/wjmh.180029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/30209896/pubmed" id="30209896" target="_blank">30209896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8846625">
<a name="8846625"></a>Steiner JF. Clinical pharmacokinetics and pharmacodynamics of finasteride. <i>Clin Pharmacokinet.</i> 1996;30(1):16-27. doi:10.2165/00003088-199630010-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/8846625/pubmed" id="8846625" target="_blank">8846625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12824459">
<a name="12824459"></a>Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. <i>N Engl J Med</i>. 2003;349(3):215-224. doi:10.1056/NEJMoa030660.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/12824459/pubmed" id="12824459" target="_blank">12824459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23944298">
<a name="23944298"></a>Thompson IM Jr, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. <i>N Engl J Med</i>. 2013;369(7):603-610. doi:10.1056/NEJMoa1215932.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/23944298/pubmed" id="23944298" target="_blank">23944298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21868079">
<a name="21868079"></a>Tresch S, Cozzio A, Kamarashev J, et al. T cell-mediated acute localized exanthematous pustulosis caused by finasteride. <i>J Allergy Clin Immunol</i>. 2012;129(2):589-594. doi:10.1016/j.jaci.2011.07.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/21868079/pubmed" id="21868079" target="_blank">21868079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-USHHS.2016">
<a name="USHHS.2016"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 27, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28319231">
<a name="28319231"></a>Welk B, McArthur E, Ordon M, Anderson KK, Hayward J, Dixon S. Association of suicidality and depression with 5α-reductase inhibitors. <i>JAMA Intern Med</i>. 2017;177(5):683-691. doi:10.1001/jamainternmed.2017.0089.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/28319231/pubmed" id="28319231" target="_blank">28319231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12639651">
<a name="12639651"></a>Wessells H, Roy J, Bannow J, et al; PLESS Study Group. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. <i>Urology</i>. 2003;61(3):579-584. doi:10.1016/s0090-4295(02)02401-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/12639651/pubmed" id="12639651" target="_blank">12639651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10674382">
<a name="10674382"></a>Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. <i>J Investig Dermatol Symp Proc</i>. 1999;4(3):282-284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/10674382/pubmed" id="10674382" target="_blank">10674382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35509334">
<a name="35509334"></a>Yamada T. Photosensitivity reaction induced by finasteride. <i>J Gen Fam Med</i>. 2021;23(3):185-186. doi: 10.1002/jgf2.510<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/35509334/pubmed" id="35509334" target="_blank">35509334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30287313">
<a name="30287313"></a>Zakhem GA, Motosko CC, Mu EW, Ho RS. Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review. <i>J Am Acad Dermatol</i>. 2019;80(4):957-969. doi:10.1016/j.jaad.2018.09.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/30287313/pubmed" id="30287313" target="_blank">30287313</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8447 Version 405.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
